OncoMatch/Clinical Trials/NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Is NCT06400472 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for ovarian neoplasms.
Treatment: Sofe-M · bevacizumab · carboplatin · Itraconazole · pembrolizumab — The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Pancreatic Cancer
Colorectal Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth · Scottsdale, Arizona
- University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, California
- Emory University · Atlanta, Georgia
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, Michigan
- NYU Langone Health - Long Island · Mineola, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06400472 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages